Are another 5 years of adjuvant aromatase inhibitor therapy needed?

Abstract

Qin-Guo Mo*, De-Quan Li*, Jian-Hong Zhong, Chang-Yuan Wei Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People’s Republic of China *These authors contributed equally to this workIn the recent issue of Breast Cancer: Targets and Therapy, some questions about adjuvant systemic therapy1 and bone loss and skeletal-related events in postmenopausal women with hormone receptor-positive breast cancer2 were discussed by two reviews.View original paper by Leone and colleagues.

Keywords

• breast cancer
• adjuvant endocrine therapy